Revolution Medicines, Inc. (RVMD) key performance indicators and operating metrics (3 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| First royalty monetization tranche from Royalty Pharma | 250M | FY2025-Q3 |
| RMC6236 patients treated to date (safety evaluable) | 127.00 | FY2024-Q2 |
| Non-cash GAAP collaboration accounting adjustment reducing collaboration revenue | 4.6M | FY2022-Q3 |
Back to RVMD overview · RVMD earnings · RVMD holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.